Study ID
|
Age median, (IQR), Male %
|
TCZ arm
(follow up)
|
Routine treatment
|
Outcomes (combinable and not combinable)
|
Events
TCZ (control)
|
Events
TCZ (control)
|
Campochiaro C. et al (Campochiaro et al., 2020)
|
TCZ:
64 (53 – 75), 90.6
Control:
60 (55-75.5), 81.8
|
IV 400 mg once, 2nd dose if needed (28 days)
|
HCQ, lopinavir/ritonavir, ceftriaxone,
azithromycin, enoxaparin
|
1-Mortality
|
5/32 (11/33)
|
5/32 (11/33)
|
|
|
|
|
2- Requirement of MV |
0/32 (3/33) |
0/32 (3/33) |
|
|
|
|
3- Hospital Discharge |
20/32 (16/33) |
20/32
(16/33) |
|
|
|
|
4- Clinical improvement |
22/32 (20/33) |
22/32
(20/33) |
|
|
|
|
5- Serious adverse events |
8/32 (9/33) |
8/32
(9/33) |
|
|
|
|
6- Bacteremia |
4/32 (4/33) |
4/32 (4/33) |
|
|
|
|
7- pulmonary embolism |
2/32 (3/33) |
2/32 (3/33) |
|
|
|
|
8- Elevated liver functions |
5/32 (6/33) |
5/32
(6/33) |
|
|
|
|
9- Neutropenia |
5/32 (0/33) |
5/32 (0/33) |
|
|
|
|
10- Changes in respiratory support
|
Improved 24/32 (20/33)
Worsened 5/32 (12/33)
No change 3/32 (1/33)
|
Improved 24/32 (20/33)
Worsened 5/32 (12/33)
No change 3/32 (1/33)
|
Guaraldi G.
et al (Guaraldi et al., 2020)
|
TCZ:
63 (54–72), 72.7
Control:
69 (57–78), 63.6
|
IV 8mg/kh, Max 800, twice (14 days)
|
Oxygen supply,
HCQ, azithromycin,
lopinavir–ritonavir
and low molecular weight heparin
|
1-Mortality
|
6/88 (73/365)
|
6/88 (73/365)
|
|
|
|
|
2- Requirement of MV |
16/88 (57/365) |
16/88
(57/365) |
|
|
|
|
3- Serious adverse events |
1/179 (0/365) |
1/179
(0/365) |
|
|
|
|
5- Bacteremia |
3/179 (4/365) |
3/179 (4/365) |
|
|
|
|
6- New infections |
24/179 (14/965) |
24/179
(14/965) |
|
|
|
|
7- Elevated liver functions |
0/179 (1/365) |
0/179
(1/365) |
|
|
|
|
8- Neutropenia |
1/179 (0/365) |
1/179 (0/365) |
Colaneri M. et al (Colaneri et al., 2020)
|
TCZ:
63.74 (16.32), 90.5
Control:
62.33 (18.68), 69.2
|
IV 8mg/kh, Max 800, twice (7 days)
|
HCQ, azithromycin,
low weight heparin, and methylprednisolone
|
1-Mortality
|
5/21 (19/91)
|
5/21 (19/91)
|
|
|
|
|
2- ICU admission |
3/21 (12/91) |
3/21 (12/91) |
Kewan T. et al (Kewan et al., 2020)
|
TCZ:
62 (53- 71), 71.4
Control:
62 (53 - 71), 47.8
|
IV 8mg/kh, Max 400 (21 days)
|
HCQ, Azithromycin
|
1-Mortality
|
3/28 (2/23)
|
3/28 (2/23)
|
|
|
|
|
2- Requirement of MV |
2/9 (6/18) |
2/9 (6/18) |
|
|
|
|
3- Hospital Discharge |
11/28 (13/23) |
11/28
(13/23) |
|
|
|
|
4- Clinical improvement |
18/28 (13/23) |
18/28
(13/23) |
|
|
|
|
5- New infections |
5/28 (5/23) |
5/28 (5/23) |
|
|
|
|
6- Changes in respiratory support
|
Improved 18/28 (13/23)
Worsened 5/28 (6/23)
No change 5/28 (4/23)
|
Improved 18/28 (13/23)
Worsened 5/28 (6/23)
No change 5/28 (4/23)
|
Somers EC. et al (Somers, Eschenauer, Troost, Golob,
Gandhi, Wang, Zhou, Petty, Baang, Dillman, et al., 2020)
|
TCZ:
55 ± 14.9, 68
Control:
60 ± 14.5, 64.5
|
8 mg/kg (maximum
800 mg) once (28 days)
|
HCQ, Redmsivir (only 2 patients in each group, NSAIDs, Acetaminophen and
anticoagulants
|
1- Mortality
|
14/78 (27/76)
|
14/78 (27/76)
|
|
|
|
|
2- New infections |
42/78 (20/76) |
42/78 (20/76) |
Ip A. et al (Ip et al., 2020)
|
TCZ:
62 (53–70), 73.9
Control:
69 (58–77), 62.2
|
IV 400mg single, second dose given to small number of patients (28
days)
|
HCQ, azithromycin
|
1-Mortality
|
1-Mortality
|
12/134 (25/413)
|
|
|
|
|
2- Bacteremia |
2- Bacteremia |
60/134 (227/413) |
|
|
|
|
3- New infections |
3- New infections |
12/134
(25/413) |